Kyowa Kirin Pharmaceutical Development
KYKOYDrugs in Pipeline
28
Phase 3 Programs
17
Upcoming Catalysts
1
Next Catalyst
Nov 2026
Market Overview
Stock performance and key metrics
1 upcoming, 1 past
KHK7580
Parathyroid Carcinoma
Vorinostat
Cutaneous T-Cell Lymphoma
Istradefylline (KW-6002)
Parkinson's Disease
KW-6500
Parkinson's Disease
KHK4827
Psoriasis
Istradefylline
Parkinson's Disease
KHK7791
Hyperphosphatemia
KW-0761
Adult T-cell Leukemia-lymphoma
Oral Phosphate Supplement
X-Linked Hypophosphatemia
EN3267
Pain
Burosumab
X-linked Hypophosphatemia (XLH)
KRN23
Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome
KW-2246 (fentanyl citrate)
Pain, Cancer
Romiplostim
Aplastic Anemia
KW-3357
Disseminated Intravascular Coagulation (DIC)
darbepoetin alfa
Anemia
OPC-262
Diabetes, Type 2
KHK4951
Diabetic Macular Edema (DME)
Mogamulizumab
Cutaneous T-Cell Lymphoma, Relapsed
ARQ 197
Non-small-cell Lung Cancer
KHK4083
Atopic Dermatitis
KW-6356
Parkinson's Disease
Pegfilgrastim
Peripheral Blood Stem Cell Transplantation
DA-EPOCH Protocol
T Cell Lymphoma
KRN7000
Chronic Hepatitis C
Topical NO
Anogenital Warts
SHP674
Acute Lymphoblastic Leukemia
KW-6002 (istradefylline)
Parkinson's Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
KHK7580 | Phase 3 | Parathyroid Carcinoma | - | - |
Vorinostat | Phase 3 | Cutaneous T-Cell Lymphoma | - | - |
Istradefylline (KW-6002) | Phase 3 | Parkinson's Disease | - | - |
KW-6500 | Phase 3 | Parkinson's Disease | - | - |
KHK4827 | Phase 3 | Psoriasis | - | - |
Istradefylline | Phase 3 | Parkinson's Disease | - | - |
KHK7791 | Phase 3 | Hyperphosphatemia | - | - |
KW-0761 | Phase 3 | Adult T-cell Leukemia-lymphoma | - | - |
Oral Phosphate Supplement | Phase 3 | X-Linked Hypophosphatemia | - | - |
EN3267 | Phase 3 | Pain | - | - |
Burosumab | Phase 3 | X-linked Hypophosphatemia (XLH) | - | - |
KRN23 | Phase 3 | Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome | - | - |
KW-2246 (fentanyl citrate) | Phase 3 | Pain, Cancer | - | - |
Romiplostim | Phase 3 | Aplastic Anemia | - | - |
KW-3357 | Phase 3 | Disseminated Intravascular Coagulation (DIC) | - | - |
darbepoetin alfa | Phase 3 | Anemia | - | - |
OPC-262 | Phase 3 | Diabetes, Type 2 | - | - |
KHK4951 | Phase 2 | Diabetic Macular Edema (DME) | - | - |
Mogamulizumab | Phase 2 | Cutaneous T-Cell Lymphoma, Relapsed | - | - |
ARQ 197 | Phase 2 | Non-small-cell Lung Cancer | - | - |
KHK4083 | Phase 2 | Atopic Dermatitis | - | - |
KW-6356 | Phase 2 | Parkinson's Disease | - | - |
Pegfilgrastim | Phase 2 | Peripheral Blood Stem Cell Transplantation | - | - |
DA-EPOCH Protocol | Phase 2 | T Cell Lymphoma | - | - |
KRN7000 | Phase 2 | Chronic Hepatitis C | - | - |
Topical NO | Phase 2 | Anogenital Warts | - | - |
SHP674 | Phase 2 | Acute Lymphoblastic Leukemia | - | - |
KW-6002 (istradefylline) | Phase 2 | Parkinson's Disease | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Kyowa Kirin Pharmaceutical Development's drug pipeline?→
CatalystAlert tracks 28 drug candidates in Kyowa Kirin Pharmaceutical Development's (KYKOY) pipeline across Phase 3, Phase 2. Its lead program is KHK7580 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Kyowa Kirin Pharmaceutical Development's next FDA catalyst?→
Kyowa Kirin Pharmaceutical Development's (KYKOY) next tracked catalyst is a Phase 2 expected August 31, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track KYKOY biotech catalysts?→
Add KYKOY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Kyowa Kirin Pharmaceutical Development's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.